Urinary incontinence: economic burden and new choices in pharmaceutical treatment.

@article{Levy2006UrinaryIE,
  title={Urinary incontinence: economic burden and new choices in pharmaceutical treatment.},
  author={Richard A. Levy and Nancy Muller},
  journal={Advances in therapy},
  year={2006},
  volume={23 4},
  pages={556-73}
}
In the year 2000, an estimated 17 million community-dwelling adults in the United States had daily urinary incontinence (UI), and an additional 33 million suffered from the overlapping condition, overactive bladder. Estimates of the total annual cost of these conditions range up to 32 billion US dollar; the largest components are management costs and the expenses associated with nursing home admissions attributable to UI. In most cases, patients with UI can be treated with pharmaceutical agents… CONTINUE READING